naxitamab

Trials studying naxitamab

• phase2Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrowactive not recruitingn=122
• phase1Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastomarecruitingn=18
• phase2Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5not yet recruitingn=10
• phase2Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)recruitingn=31
• phase2Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastomarecruitingn=93
• phase2Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastomaterminatedn=2
• phase4Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.not yet recruitingn=62